Predict your next investment

Neuracle Science company logo
HEALTHCARE | Biotechnology
neuracles.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series C | Alive

Total Raised

$44.08M

Last Raised

$29.57M | 3 yrs ago

About Neuracle Science

Neuracle Science is a Korean biotech firm that develops treatments for neurodegenerative disorders including Alzheimer's disease, neuropathic pain, ALS, and schizophrenia.

Neuracle Science Headquarter Location

Sanhakgwan 702-2 145, Anam-ro, Seongbuk-gu

Seoul, 02841,

South Korea

+82 02 6949 0409

Latest Neuracle Science News

CJ Healthcare invests W2b in Alzheimer’s disease drug developer

Jul 2, 2019

PUBLISHED :March 07, 2017 - 15:50 UPDATED :March 07, 2017 - 15:50 [THE INVESTOR]  CJ Healthcare, the pharmaceutical unit of CJ Group, said on March 7 that it has made investment in a Korean biotech startup developing treatments for dementia. CJ Healthcare will invest 2 billion won (US$1.74 million) in Neuracle Science, which is working on Alzheimer’s treatment developing projects, as a part of its 15.2 billion won worth venture capital fund it set up with Timewise Investment, CJ Group’s investment affiliate. This fund, run by Timewise Investment, was formed to create an industry ecosystem where pharmaceutical companies and startups can co-exist, and to establish pharmaceutical direct investment funds and promote open innovation,” CJ Healthcare said in a press release. Neuracle Science is seeking to discover the lead antibody which inhibits a factor of reactive gliosis caused by nerve damage or degenerative brain diseases. The company is currently working on the selection of potential cancer drug target candidates through preclinical animal studies and expects to start clinical trials by 2019. So far, it has confirmed the involvement of gliosis in Alzheimer’s disease mice model over normal mice model and also confirmed considerable reducing of gliosis in Alzheimer’s disease mice model with injection of monoclonal lead antibody that specifically neutralizes the gliosis-inducing novel ligand. Last year, the project by Neuracle Science was also backed by the Korea Drug Development Fund, a government-initiated drug development program by a consortium of health care related Korean ministries. By Park Han-na (hnpark@heraldcorp.com)

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Neuracle Science

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Neuracle Science is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Neuracle Science Patents

Neuracle Science has filed 15 patents.

The 3 most popular patent topics include:

  • Chromosomes (human)
  • Human proteins
  • Neurological disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/27/2018

10/26/2021

Autoimmune diseases, Clusters of differentiation, Immunology, Monoclonal antibodies, Rare diseases

Grant

Application Date

6/27/2018

Grant Date

10/26/2021

Title

Related Topics

Autoimmune diseases, Clusters of differentiation, Immunology, Monoclonal antibodies, Rare diseases

Status

Grant

Neuracle Science Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Neuracle Science Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.